Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation.

Effective expansion of T-cells without ex vivo stimulation and maintenance of their antitumor functions in the complex tumor microenvironment (TME) are still daunting challenges in T-cell-based immunotherapy. Here, we developed biomimetic artificial antigen-presenting cells (aAPCs), ultrathin MnOx nanoparticles (NPs) functionalized with T-cell activators (anti-CD3/CD28 mAbs, CD), and tumor cell membranes (CMs) for enhanced lung metastasis immunotherapy. The aAPCs, termed CD-MnOx@CM, not only efficiently enhanced the expansion and activation of intratumoral CD8+ cytotoxic T-cells and dendritic cells after homing to homotypic metastatic tumors but also regulated the TME to facilitate T-cell survival through catalyzing the decomposition of intratumoral H2O2 into O2. Consequently, the aAPCs significantly inhibited the development of lung metastatic nodules and extended the survival of a B16-F10 melanoma metastasis model, while minimizing adverse events. Our work represents a new biomaterial strategy of inhibiting tumor metastasis through targeted TME regulation and in situ T-cell-based immunotherapy.

[1]  Zhongmin Yang,et al.  Catalytic‐Enhanced Lactoferrin‐Functionalized Au‐Bi2Se3 Nanodots for Parkinson's Disease Therapy via Reactive Oxygen Attenuation and Mitochondrial Protection , 2021, Advanced healthcare materials.

[2]  Tianwu Chen,et al.  Gadolinium-hyaluronic acid nanoparticles as an efficient and safe magnetic resonance imaging contrast agent for articular cartilage injury detection , 2020, Bioactive materials.

[3]  Jun Lin,et al.  MnOx Nanospikes as Nanoadjuvants and Immuogenic Cell Death Drugs with Enhanced Antitumor Immunity and Antimetastatic Effect. , 2020, Angewandte Chemie.

[4]  Michael L. Wang,et al.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. , 2020, The New England journal of medicine.

[5]  Jun Lin,et al.  Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications , 2020, Advanced materials.

[6]  Zhongmin Yang,et al.  Ultralong tumor retention of theranostic nanoparticles with short peptide-enabled active tumor homing. , 2019, Materials horizons.

[7]  Michael S. Goldberg,et al.  Improving cancer immunotherapy through nanotechnology , 2019, Nature Reviews Cancer.

[8]  Yu Chen,et al.  Nanocatalytic Medicine , 2019, Advanced materials.

[9]  S. Gerecht,et al.  Engineering an Artificial T‐Cell Stimulating Matrix for Immunotherapy , 2019, Advanced materials.

[10]  Xiaogang Qu,et al.  Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications. , 2019, Chemical reviews.

[11]  Zhuang Liu,et al.  Nanoparticle‐Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy , 2019, Advanced materials.

[12]  Kanyi Pu,et al.  Recent Advances in Cell Membrane-Camouflaged Nanoparticles for Cancer Phototherapy. , 2018, Small.

[13]  Shobha Ghosh,et al.  Leutusome: A Biomimetic Nanoplatform Integrating Plasma Membrane Components of Leukocytes and Tumor Cells for Remarkably Enhanced Solid Tumor Homing. , 2018, Nano letters.

[14]  P. Guldberg,et al.  Adoptive T cell cancer therapy , 2018, Nature Materials.

[15]  Xiaoqi Sun,et al.  Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. , 2018, ACS nano.

[16]  Wenbin Lin,et al.  Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy. , 2018, Journal of the American Chemical Society.

[17]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[18]  Liangzhu Feng,et al.  Smart Nanoreactors for pH-Responsive Tumor Homing, Mitochondria-Targeting, and Enhanced Photodynamic-Immunotherapy of Cancer. , 2018, Nano letters.

[19]  K. Tamada,et al.  IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor , 2018, Nature Biotechnology.

[20]  Qinying Zhang,et al.  Oxygen‐Generating MnO2 Nanodots‐Anchored Versatile Nanoplatform for Combined Chemo‐Photodynamic Therapy in Hypoxic Cancer , 2018 .

[21]  David J Mooney,et al.  Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T-cells , 2017, Nature Biotechnology.

[22]  Yanqin Sun,et al.  Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy , 2017, Clinical Cancer Research.

[23]  Namrata Singh,et al.  A Redox Modulatory Mn3 O4 Nanozyme with Multi-Enzyme Activity Provides Efficient Cytoprotection to Human Cells in a Parkinson's Disease Model. , 2017, Angewandte Chemie.

[24]  Ronnie H. Fang,et al.  Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity , 2017, Advanced materials.

[25]  Zhuang Liu,et al.  Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses , 2017, Nature Communications.

[26]  Hai-Quan Mao,et al.  Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation. , 2017, Nano letters.

[27]  Pengcheng Zhang,et al.  Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy , 2017, Theranostics.

[28]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[29]  Ting Wu,et al.  Tumor microenvironment and therapeutic response. , 2017, Cancer letters.

[30]  Kai Yang,et al.  Ultrasound Triggered Tumor Oxygenation with Oxygen-Shuttle Nanoperfluorocarbon to Overcome Hypoxia-Associated Resistance in Cancer Therapies. , 2016, Nano letters.

[31]  E. Rankin,et al.  Hypoxic control of metastasis , 2016, Science.

[32]  S. Sleijfer,et al.  Adoptive T-cell therapy: a need for standard immune monitoring. , 2015, Immunotherapy.

[33]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[34]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[35]  C. Graham,et al.  Mechanisms of hypoxia-mediated immune escape in cancer. , 2014, Cancer research.

[36]  I. Svane,et al.  Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? , 2014, Cancer Immunology, Immunotherapy.

[37]  Tarek R. Fadel,et al.  A carbon nanotube-polymer composite for T-cell therapy. , 2014, Nature nanotechnology.

[38]  Siok-Keen Tey.  Adoptive T-cell therapy: adverse events and safety switches , 2014, Clinical & translational immunology.

[39]  E John Wherry,et al.  T cell exhaustion , 2011 .

[40]  L. Coussens,et al.  Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. , 2010, Cancer research.

[41]  Jiangjiexing Wu,et al.  Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II). , 2019, Chemical Society reviews.

[42]  M. Peng,et al.  Actively Targeted Deep Tissue Imaging and Photothermal‐Chemo Therapy of Breast Cancer by Antibody‐Functionalized Drug‐Loaded X‐Ray‐Responsive Bismuth Sulfide@Mesoporous Silica Core–Shell Nanoparticles , 2018, Advanced functional materials.

[43]  R. Vile,et al.  Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. , 2007, Cancer research.